Exela Didn't Infringe Alphagan IP: Fed. Circ.
The Federal Circuit on Thursday reversed a ruling that Exela PharmSci Inc.'s proposed generic version of Allergan Inc.'s glaucoma treatment Alphagan infringed a patent, while affirming an injunction on Apotex Inc.'s...To view the full article, register now.
Already a subscriber? Click here to view full article